{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:32:20Z","timestamp":1787740340913,"version":"build-2784847793"},"reference-count":64,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Newcastle University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>A total of nine TIDES (pepTIDES and oligonucleoTIDES) were approved by the FDA during 2023. The four approved oligonucleotides are indicated for various types of disorders, including amyotrophic lateral sclerosis, geographic atrophy, primary hyperoxaluria type 1, and polyneuropathy of hereditary transthyretin-mediated amyloidosis. All oligonucleotides show chemically modified structures to enhance their stability and therapeutic effectiveness as antisense or aptamer oligomers. Some of them demonstrate various types of conjugation to driving ligands. The approved peptides comprise various structures, including linear, cyclic, and lipopeptides, and have diverse applications. Interestingly, the FDA has granted its first orphan drug designation for a peptide-based drug as a highly selective chemokine antagonist. Furthermore, Rett syndrome has found its first-ever core symptoms treatment, which is also peptide-based. Here, we analyze the TIDES approved in 2023 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.<\/jats:p>","DOI":"10.3390\/ph17020243","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T04:18:22Z","timestamp":1707884302000},"page":"243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["2023 FDA TIDES (Peptides and Oligonucleotides) Harvest"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8488-2706","authenticated-orcid":false,"given":"Danah","family":"Al Shaer","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Evotec (UK) Ltd., Abingdon OX14 4R, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-1825","authenticated-orcid":false,"given":"Othman","family":"Al Musaimi","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medical Sciences, Newcastle upon Tyne NE1 7RU, UK"},{"name":"Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8946-0462","authenticated-orcid":false,"given":"Fernando","family":"Albericio","sequence":"additional","affiliation":[{"name":"School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa"},{"name":"CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8521-9172","authenticated-orcid":false,"given":"Beatriz G.","family":"de la Torre","sequence":"additional","affiliation":[{"name":"KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mullard, A. (2024). 2023 FDA approvals. Nat. Rev.","DOI":"10.1038\/d41573-024-00001-x"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Al Musaimi, O., Al Shaer, D., Albericio, F., and de la Torre, B.G. (2023). 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030336"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"de la Torre, B.G., and Albericio, F. (2024). The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules, 29.","DOI":"10.20944\/preprints202401.0523.v1"},{"key":"ref_4","unstructured":"(2024, February 08). Dicerna Pharmaceuticals GalXC\u2122 and GalXC-Plus\u2122 Technologies. Available online: https:\/\/www.novonordisk-us.com\/."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Al Shaer, D., Al Musaimi, O., Albericio, F., and de la Torre, B.G. (2020). 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 13.","DOI":"10.3390\/ph13030040"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Al Musaimi, O., Lombardi, L., Williams, D.R., and Albericio, F. (2022). Strategies for Improving Peptide Stability and Delivery. Pharmaceuticals, 15.","DOI":"10.3390\/ph15101283"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Al Shaer, D., Al Musaimi, O., Albericio, F., and de la Torre, B.G. (2022). 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020222"},{"key":"ref_8","unstructured":"(2024, February 08). QALSODY Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215887s000lbl.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"ref_10","unstructured":"(2024, February 08). IZERVAY Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217225s000lbl.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s40265-023-01948-8","article-title":"Avacincaptad Pegol: First Approval","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2\/3 Trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_13","unstructured":"(2024, February 08). RIVFLOZA Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215842s000lbl.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: First Approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","article-title":"Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria","volume":"26","author":"Lai","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_16","unstructured":"(2021, January 16). Oxlumo Approval Letter, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2020\/214103Orig1s000ltr.pdf."},{"key":"ref_17","unstructured":"(2024, February 08). WAINU Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217388s000lbl.pdf."},{"key":"ref_18","unstructured":"(2024, February 08). WAINUA\u2122 (Eplontersen). Available online: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/wainua-eplontersen-granted-first-ever-regulatory-approval-us-treatment-of-adults-with-polyneuropathy-hereditary-transthyretin-mediated-amyloidosis.html."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.3233\/JND-150091","article-title":"Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area","volume":"2","author":"Mazzeo","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care","volume":"16","author":"Luigetti","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Al Shaer, D., Al Musaimi, O., Albericio, F., and de la Torre, B.G. (2019). 2018 FDA Tides Harvest. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020052"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40291-023-00665-y","article-title":"Flotufolastat F 18: Diagnostic First Approval","volume":"27","author":"Heo","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"ref_25","unstructured":"(2024, February 08). Posluma Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216023s000lbl.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11912-021-01156-1","article-title":"The Emerging Role of Next-Generation Imaging in Prostate Cancer","volume":"24","author":"Murthy","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.37894","article-title":"(18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging","volume":"10","author":"Werner","year":"2020","journal-title":"Theranostics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0020-708X(83)90289-2","article-title":"Half-life of 68Ga","volume":"34","author":"Iwata","year":"1983","journal-title":"Appl. Radiat. Isot."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Al Musaimi, O., Al Shaer, D., Albericio, F., and de la Torre, B.G. (2021). 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020145"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2967\/jnumed.119.234922","article-title":"Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors","volume":"61","author":"Wurzer","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2967\/jnumed.121.263707","article-title":"Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer","volume":"63","author":"Kroenke","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2967\/jnumed.120.260091","article-title":"Detection efficacy of (18)F-rhPSMA-7.3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment","volume":"62","author":"Rauscher","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.121.263440","article-title":"Utility of (18)F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology","volume":"63","author":"Langbein","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s40265-023-01962-w","article-title":"Motixafortide: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"ref_35","unstructured":"(2024, February 08). Aphexda Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217159s000lbl.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/17425255.2020.1711884","article-title":"Clinical significance of chemokine receptor antagonists","volume":"16","author":"Miao","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20406207231174304","DOI":"10.1177\/20406207231174304","article-title":"Innovations in hematopoietic stem-cell mobilization: A review of the novel CXCR4 inhibitor motixafortide","volume":"14","author":"Crees","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-16-2919","article-title":"Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34(+) Cells in Healthy Volunteers","volume":"23","author":"Abraham","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Rebolledo-Bustillo, M., Garcia-Gomez, D., D\u00e1vila, E.M., Castro, M.E., Caballero, N.A., Melendez, F.J., Baizabal-Aguirre, V.M., Sanchez-Gaytan, B.L., and Perez-Aguilar, J.M. (2023). Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054393"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","article-title":"Rezafungin: First Approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"ref_42","unstructured":"(2024, February 08). Micafungin Approval Letter, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/21-506_Mycamine_Approv.pdf."},{"key":"ref_43","unstructured":"(2024, February 08). Anidulafungin Approval Letter, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/21948s000_Eraxis_Approv.pdf."},{"key":"ref_44","unstructured":"(2024, February 08). Caspofungin Approval Letter, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21227_Cancidas_Approv.pdf."},{"key":"ref_45","unstructured":"(2024, February 08). Rezzayo Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217417s000lbl.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Garcia-Effron, G. (2020). Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins. J. Fungi, 6.","DOI":"10.3390\/jof6040262"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): A multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Thompson, G.R., Soriano, A., Honore, P.M., Bassetti, M., Cornely, O.A., Kollef, M., Kullberg, B.J., Pullman, J., Hites, M., and Fort\u00fan, J. (2023). Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: Pooled data from two prospective randomised controlled trials. Lancet Infect. Dis.","DOI":"10.1016\/S1473-3099(23)00551-0"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: A randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","article-title":"NNZ-2566: A Gly\u2013Pro\u2013Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke","volume":"278","author":"Bickerdike","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_52","first-page":"723","article-title":"On a unusual brain atrophy syndrome in hyperammonemia in childhood","volume":"116","author":"Rett","year":"1966","journal-title":"Wien Med. Wochenschr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ana.22124","article-title":"Rett syndrome: Revised diagnostic criteria and nomenclature","volume":"68","author":"Jeffrey","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","article-title":"Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome","volume":"55","author":"Motil","year":"2012","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Valenti, D., and Vacca, R.A. (2023). Brain Mitochondrial Bioenergetics in Genetic Neurodevelopmental Disorders: Focus on Down, Rett and Fragile X Syndromes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512488"},{"key":"ref_56","unstructured":"(2024, February 08). Daybue Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217026s000lbl.pdf."},{"key":"ref_57","unstructured":"(2024, February 08). Zilbrysq Drug Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1213920","DOI":"10.3389\/fimmu.2023.1213920","article-title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","volume":"14","author":"Tang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","article-title":"Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway","volume":"120","author":"Krisinger","year":"2012","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ebiom.2016.02.011","article-title":"Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin","volume":"5","author":"Foley","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-016-1107-2","article-title":"Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial","volume":"15","author":"Karpova","year":"2017","journal-title":"J. Transl. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/2\/243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:59:11Z","timestamp":1760104751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/2\/243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ph17020243"],"URL":"https:\/\/doi.org\/10.3390\/ph17020243","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]}}}